Sagetis leads LBLONCOVIRUS project

January 1, 2016

A consortium led by Sagetis receives 0.5M€ for developing new adenoviral nanoparticulate system for the treatment of pancreatic adenocarcinoma.

 

Barcelona – January 2016 – Sagetis is pleased to announce that MINECO has granted funding to the LBLONCOVIRUS project (RTC-2015-4189-1) – Polymeric multilayer coating of oncolytic adenovirus for the regulation of their tropism against pancreatic adenocarcinoma.

 

The consortium led by Sagetis also involves research groups from IQS (GEMAT) and IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer). The consortium will receive €0.5M funding from the Ministerio de Economía y Competitividad (MINECO), programa RETOS DE COLABORACIÓN, 2015.

 

The main goal of LBLONCOVIRUS consortium is to develop a new adenoviral nanoparticulate system artificially coated with a functionalized polymer multilayer system for the treatment of pancreatic cancer, one of the most devastating and lethal cancers in today’s society. The new system is intended to increase both the efficacy and safety profile of the nude viral particles while at the same time overcoming the immune response associated with the adenoviruses.

 

About Sagetis Biotech

 

Sagetis Biotech is a biotechnology company focused on developing innovative drug delivery technologies for unmet medical needs. Based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.

 

The company's versatile, polymeric-based platforms are designed to tackle highly challenging areas, such as the delivery of drugs through difficult-to-cross barriers(e.g. blood-brain barrier, intestinal mucus gel layer, ocular) and the efficient transfection of genetic material, using both viral and non-viral vectors.

 

About IQS-GEMAT

 

The Grup d’Enginyeria de Materials was founded in the year 1994 by Dr. Salvador Borrós, a current Full Professor in Material Science, with the objective of giving research service to the teaching community on this subject. From the beginning, the Group’s efforts were driven to the field of polymeric materials, specially elastomers, conductive polymers and surface treatment.

 

By this time, the main research fields have been established: conductive polymers, rubber, ceramic materials and surface modification. In 2003, the Group organizes in Barcelona the 1st Workshop in Bioengineering. In the year 2004, the 2nd Workshop takes place, now with the support of the IQS; the 3rd and 4th events were to follow. The IQS has been, through the Group, the founder of the European Technological Platform in Nanomedicine

 

About IDIBAPS

 

IDIBAPS is a research Institute that combines clinical research of proven quality with high-level basic research to achieve effective transfer of scientific advances in the prevention and treatment of the most common health problems. The IDIBAPS scientific staff come from its constituent institutions: Hospital Clínic de Barcelona, the University of Barcelona School of Medicine, the CSIC’s Barcelona Biomedical Research Institute and the staff recruited by the Fundació Clínic. The IDIBAPS is organized into five major areas of research with more than 450 investigators.

 

The Gene Therapy and Cancer Group at IDIBAPS, led by Dr. Cristina Fillat  focus its research in pancreatic cancer. The group is particularly interested in the identification of specific cellular pathways and molecular determinants involved in pancreatic tumor biology and in the development of therapeutic strategies based on oncolytic adenovirus.

 

 

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

SAGETIS BIOTECH GRANTS EXCLUSIVE LICENSE OF ITS VIROSHIELD TECHNOLOGY TO ARATINGA.BIO TNP FOR RETROVIRAL AND PLASMID-BASED APPLICATIONS

March 29, 2019

1/4
Please reload

Recent Posts
Please reload

© 2018 - Sagetis Biotech | Via Augusta 394 –  08017 - Barcelona (SPAIN)

www.sagetis-biotech.com | Privacy Policy